TLDR
A bioequivalence study proves that a generic or reformulated drug product delivers the same rate and extent of absorption as its reference listed drug. FDA sets the acceptance criterion at a 90% confidence interval of 80-125% for Cmax and AUC. For pharmaceutical and biotech organizations, managing the data, documents, and quality events tied to a BE program requires a validated quality management system at every step.
What Is a Bioequivalence Study?
A bioequivalence study establishes that a test drug product and a reference listed drug (RLD) produce statistically equivalent pharmacokinetic (PK) profiles in human subjects, or through validated in vitro methods when applicable. The FDA defines bioequivalence as the absence of a significant difference in the rate and extent to which the active ingredient in pharmaceutical equivalents becomes available at the site of drug action under similar conditions. (FDA)
The gold standard metric is the 90% confidence interval (CI) for the geometric mean ratio of the test and reference products for Cmax (peak plasma concentration) and AUC (area under the plasma concentration-time curve). Both parameters must fall within 80-125% for the product to meet the standard bioequivalence acceptance criterion. Narrow therapeutic index (NTI) drugs carry tighter criteria, typically 90-111%.
Bioavailability, the fraction of a dose that reaches systemic circulation intact, is the foundational pharmacokinetic measurement from which bioequivalence is derived. When two products are bioequivalent, FDA considers them therapeutically equivalent and substitutable.
When Is a Bioequivalence Study Required?
Several regulatory pathways trigger the requirement for a BE study.
Abbreviated New Drug Applications. Every generic drug seeking FDA approval through an ANDA (Abbreviated New Drug Application) must include BE data demonstrating equivalence to the RLD. This is the most common trigger for bioequivalence testing in the generic pharmaceutical industry.
SUPAC Changes. The FDA's SUPAC (Scale-Up and Post-Approval Changes) guidances define which post-approval changes require in vivo BE data and which qualify for an in vitro waiver. Site transfers, formulation changes, and manufacturing scale-up beyond defined thresholds may each require BE bridging studies, depending on the level of change. (FDA SUPAC)
New Formulations and Strengths. Sponsors developing a new formulation, an out-of-range strength, or a new dosage form of an existing drug product typically need bioequivalence testing to bridge the new and original presentations.
NDA Post-Approval Supplements. Certain post-approval changes to an approved NDA, such as changes to the active pharmaceutical ingredient source or key manufacturing process steps, may require in vivo BE data as part of the supplement package.
Types of Bioequivalence Studies
FDA recognizes several study designs, and the right one depends on the drug's biopharmaceutic properties and the regulatory context.
In Vivo Pharmacokinetic Studies
The standard design is a single-dose, two-period, two-sequence crossover study in healthy adult volunteers. Subjects receive the test and reference products in separate study periods, with a washout interval of at least five terminal half-lives between periods. Blood samples are collected at pre-specified timepoints, and plasma drug concentrations are quantified using a validated bioanalytical method. PK parameters (Cmax, AUC0-t, AUC0-inf, Tmax) are calculated and submitted to the FDA for statistical review.
For highly variable drugs (HVDs), replicate crossover designs or reference-scaled average bioequivalence (RSABE) criteria apply under specific FDA product-specific guidance. (FDA)
In Vitro Dissolution (Comparative)
For certain immediate-release solid oral dosage forms, comparative dissolution profiling at multiple pH values can support a bioequivalence determination, particularly when combined with formulation composition similarity data. Profiles are compared using the f2 similarity factor; an f2 value of 50 or above indicates dissolution profile similarity.
BCS-Based Biowaivers
The Biopharmaceutics Classification System (BCS) classifies active substances by solubility and intestinal permeability. BCS Class I drugs (high solubility, high permeability) and BCS Class III drugs (high solubility, low permeability) meeting specific criteria may qualify for a biowaiver, which replaces in vivo BE requirements with in vitro dissolution data. The ICH M9 guideline, adopted by FDA in 2021, provides the current framework for BCS-based biowaivers. (ICH M9, FDA M9 Guidance)
PD and Clinical Endpoint Studies
For drug products where PK measurements are not feasible, such as topical or locally acting formulations, pharmacodynamic (PD) studies or clinical endpoint BE studies may be required. These are more resource-intensive and apply to specific drug categories where systemic plasma concentrations do not reflect clinical effect at the target site.
Bioequivalence Study Design Requirements
A compliant BE study rests on a protocol that meets FDA expectations for subject selection, sampling schedules, bioanalytical method validation, and statistical power. Core design requirements include:
- An IRB-approved protocol with a pre-specified statistical analysis plan
- Adequate subject enrollment to achieve at least 80% power within the 80-125% acceptance criterion
- Validated bioanalytical methods consistent with the FDA's Bioanalytical Method Validation (BMV) guidance
- A washout period of at least five terminal half-lives between treatment periods in crossover designs
- Pre-dose and timed post-dose blood sample collection matched to the drug's expected PK profile
- Documented subject safety monitoring and adverse event reporting procedures
The FDA's 2024 guidance on Data Integrity for In Vivo Bioavailability and Bioequivalence Studies reinforces that all BE study data, from raw chromatographic files to subject dosing records, must comply with ALCOA+ principles: Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available.
QMS Requirements for BE Study Data Management
FDA inspectors do not just review BE data. They examine the quality systems that generated and documented it. A QMS supporting pharmaceutical R&D must address the following areas.
Data Integrity and Electronic Records
All electronic records generated during a BE study, including bioanalytical data, dosing logs, and PK calculations, must reside in systems with complete and tamper-evident audit trails. 21 CFR Part 11 sets the controls for electronic records and electronic signatures used in FDA-regulated submissions. Every data entry, modification, and deletion must carry a date/time stamp and the identity of the user responsible.
Protocol and Document Control
A controlled document management system governs the BE protocol, amendments, SOPs, and the analytical procedure used to validate the bioanalytical method. Each document must pass a formal review and approval workflow before use, and version control must prevent confusion between current and superseded versions.
Deviation Handling
Deviations from the approved protocol are a routine reality in clinical and bioanalytical operations. Each deviation requires a formal deviation report, a documented quality assessment of its impact on data validity, and review and disposition by the quality unit before the analytical report is finalized. Protocol deviations that affect data integrity or the statistical plan may require disclosure to the FDA within the study report. A structured deviation CAPA process ensures root cause analysis and preventive actions are documented and verified.
Lab Records and Batch Documentation
Bioanalytical labs must maintain contemporaneous records for each analytical run, calibration curves, quality control samples, and instrument logs. These records, combined with subject dosing and sample collection documentation, form the evidentiary backbone of the BE submission. Accurate batch-level records, including reagent lot numbers and calibration status for each instrument, are required for GLP compliance.
How an eQMS Supports Bioequivalence Program Management
Coordinating the documentation, quality events, and regulatory outputs of a BE program across disconnected systems, spreadsheets, or paper-based workflows introduces data integrity risk at every stage. A purpose-built eQMS consolidates these processes into a single validated platform.
Cloudtheapp provides the infrastructure generic drug developers and biotech R&D organizations need to manage their BE programs efficiently and in full regulatory compliance.
Lab Testing. Cloudtheapp's Lab Testing module supports the full lifecycle of bioanalytical operations: method management, sample tracking, result entry, out-of-specification (OOS) investigation, and run-level documentation. Every lab record is created, reviewed, and approved within the system, with complete audit trail capture on all entries and modifications.
Batch Records. For SUPAC bridging studies or post-approval change scenarios, Cloudtheapp's electronic Batch Records module ties manufacturing batch data directly to the BE documentation package. Every batch variable, from the active ingredient lot to key process parameters, is documented and traceable to the study record.
Deviations. Cloudtheapp's Deviations module routes protocol and analytical deviations through a structured assessment and disposition workflow. Quality teams can evaluate impact, assign CAPAs, and link deviation records directly to the associated study protocol, keeping clinical operations and the quality function fully aligned throughout the study.
Documents. Cloudtheapp's controlled document management handles the full lifecycle of BE study documentation: protocols, amendments, bioanalytical SOPs, validation reports, and final study reports. Review and approval workflows enforce signature requirements, and complete version history is maintained automatically.
Regulatory Dossiers and Submissions. After study completion, the BE report and supporting data packages must be organized and submitted to the FDA as part of an ANDA or NDA supplement. Cloudtheapp's Regulatory Dossiers and Submissions module gives regulatory affairs teams a structured, controlled environment to build, review, and manage submission-ready content.
21 CFR Part 11 Compliance. Cloudtheapp is a fully validated, FDA-compliant eQMS. Its audit trail infrastructure spans every module and every record type, giving sponsors the documented proof of data integrity that FDA inspectors require when reviewing BE study records.
The Bottom Line
A bioequivalence study is one of the most data-intensive and regulatory-sensitive activities a pharmaceutical or biotech organization undertakes. Fragmented lab records, uncontrolled deviations, and poorly managed documentation are among the most common causes of FDA complete response letters and data integrity findings tied to BE submissions.
A validated eQMS purpose-built for regulated pharmaceutical operations removes those risks. It brings protocol management, lab records, deviation handling, batch documentation, and regulatory submission management into a single compliant environment, so your quality team can focus on the science.
Ready to see how Cloudtheapp supports your bioequivalence program? Request a Demo at cloudtheapp.com.
Sources: